Skip to content

The effect of niacin in the treatment of depression

Evaluation of niacin addition to Escitalopram in patients with depression

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231207060286N1
Enrollment
66
Registered
2023-12-17
Start date
2024-01-09
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Major depressive disorder, single episode, mild

Interventions

Intervention 1: Intervention group: The intervention group (33 people) will receive niacin (Abidi Pharmaceuticals co.) supplement in addition to EScitalopram (Abidi Pharmaceuticals co.) as an anti-dep

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Score 11 to 18 in Hamilton depression test Diagnosis of mild and moderate depression based on structured interview based on DSM-5 and Hamilton index Age 18 to 60 years

Exclusion criteria

Exclusion criteria: Received electric shock in the last two months Thyroid diseases Psychotic disorder pregnant women severe depression Allergy to niacin

Design outcomes

Primary

MeasureTime frame
Depression score. Timepoint: Before the intervention, 2, 4, and 8 weeks after the intervention. Method of measurement: Clinical examination with Hamilton's index.

Secondary

MeasureTime frame
Side effects of niacin. Timepoint: Before the intervention, 2, 4, and 8 weeks after the intervention. Method of measurement: Clinical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamhasan Esfahani

Ahvaz University of Medical Sciences

esfahani.gh@ajums.ac.ir+98 915 572 4252

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026